Entremed Inc - ENMD- Profile

Entremed Inc. The Group's principal activity is to sponsor and conduct research and development of therapeutics primarily for the treatment of cancer. The Group's lead drug candidate Panzem(R) (2-methoxyestradiol or 2ME2) is currently being tested as a cancer therapeutic in four Phase 2 clinical trials and has been granted United States Food and Drug Administration (FDA) Orphan Drug designation in three cancer indications. The Group's other drug candidate MKC-1, a novel cell cycle inhibitor, is also in Phase 2 clinical trials for cancer. It is seeking strategic alliances, licensing relationships and co-development partnerships with other companies to develop compounds for both oncology and non-oncology therapeutic areas. The Group operates in the United States. On 11-Jan-2006, the Group acquired Miikana Therapeutics, Inc. Develops angiogenic therapeutic products that target abnormal blood vessel growth